Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials

 Abstract

Combination antiretroviral therapy (cART) has transformed HIV from a deadly to a chronic disease, but HIV patients are still burdened with excess morbidity and mortality, long-term toxicities from cART, stigmatization, and insufficient access to cART worldwide. Thus, a cure for HIV would have enormous impact on society as well as the individual. As the complexity and mechanisms of HIV persistence during therapy are being unraveled, new therapeutic targets for HIV eradication are discovered. Substances that activate HIV production in the latently infected cells have recently received much attention. By turning on expression of latent HIV proviruses, reactivation strategies could contribute to the eradication HIV infection. Compounds that are currently being or soon to be tested in clinical trials are emphasized. The results from these trials will provide important clues as to whether or not reactivating strategies could become significant components of a cure for HIV.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
790 - 799
doi
10.4161/hv.23202
Type
Review
Group
Immunotherapy
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials